U.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia APRNewsWire • 06/29/23
BioMarin: Decision Day For Hemophilia Gene Therapy Upcoming - Approval LikelySeeking Alpha • 06/29/23
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis (ISTH) 2023 CongressPRNewsWire • 06/22/23
Why PTC Therapeutics Could Be Victorious In Its Rare-Disease Battle Against BioMarin PharmaceuticalsInvestors Business Daily • 05/17/23
BioMarin (BMRN) Reports Q1 Earnings: What Key Metrics Have to SayZacks Investment Research • 04/27/23
BioMarin Pharmaceutical (BMRN) Q1 Earnings and Revenues Surpass EstimatesZacks Investment Research • 04/26/23
BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total RevenuesPRNewsWire • 04/26/23
MiNA Therapeutics Enters Research Collaboration with BioMarin Pharmaceutical to Advance RNAa Platform Research in Rare Genetic DiseasesBusiness Wire • 04/25/23
BioMarin to Host First Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, April 26, at 4:30pm ETPRNewsWire • 04/13/23
BioMarin to Share Updated Data at 2023 American College of Medical Genetics and Genomics (ACMG) Meeting Demonstrating Commitment to Understanding Long-Term Benefit of VOXZOGO® in Children with AchondroplasiaPRNewsWire • 03/14/23